PTO/SB/17 (10-03)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are required to re

FE	E	TR	AN	SMIT	TAL
	1	or	FY	2004	

Effective 10/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 0.00

espond to a collection of informa	ition unless it displays a valid OMB control number.					
Complete if Known						
Application Number	10/696,002-Conf. #7776					
Filing Date	October 30, 2003					
First Named Inventor	Jing-Shan Hu					
Examiner Name	R. S. Landsman					
Art Unit	1647					
Attorney Docket No.	PF112P3C2US					

	_					
METHOD OF PAYMENT (check all that apply)	ऻ			FEE	CALCULATION (continued)	
Check Credit Money Other None	3. A	DDITI	ONAL	FEES	i	
X Deposit Account:	١.					
Deposit		Entity		Entity	_	
Account Number 08-3425	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
Deposit Account Human Genome Sciences, Inc.	1051	130	2051	65	Surcharge – late filing fee or oath	
Name The Director is authorized to: (check all that apply)	1052	50	2052	25	Surcharge – late provisional filing fee or cover sheet.	1 1
X Charge fee(s) indicated below X Credit any overpayments	1053	130	1053	130	Non-English specification	
X Charge any additional fee(s) or any underpayment of fee(s)	1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
Charge fee(s) indicated below, except for the filing fee	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
to the above-identified deposit account.	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
FEE CALCULATION	1251	110	2251	55	Extension for reply within first month	
1. BASIC FILING FEE	1252	420	2252	210	Extension for reply within second month	
Large Entity Small Entity	1253	950	2253	475	Extension for reply within third month	
Fee Fee Fee Fee Fee Description Fee Paid	1254	1,480	2254	740	Extension for reply within fourth month	
1001 770 2001 385 Utility filing fee	1255	2,010	2255	1,005	Extension for reply within fifth month	
1002 340 2002 170 Design filing fee	1401	330	2401	165	Notice of Appeal	
1003 530 2003 265 Plant filing fee	1402	330	2402	165	Filing a brief in support of an appeal	
1004 770 2004 385 Reissue filing fee	1403	290	2403	145	Request for oral hearing	
1005 160 2005 80 Provisional filing fee	1451	1,510	1451	1,510	Petition to institute a public use proceeding	
SUBTOTAL (1) (\$) 0.00	1452	110	2452	55	Petition to revive – unavoidable	
(, (,	1453	1,330	2453	665	Petition to revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,330	2501	665	Utility issue fee (or reissue)	
Extra Fee from Claims below Fee Paid	1502	480	2502	240	Design issue fee	
Total Claims -** = x =	1503	640	2503	320	Plant issue fee	
Independent = x =	1460	130	1460	130	Petitions to the Commissioner	
Claims Multiple Dependent =	1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
Large Entity Small Entity	1806	180	1806	180	Submission of Information Disclosure Stmt	
Fee Fee Fee Fee Code (\$) Code (\$)	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1202 18 2202 9 Claims in excess of 20 1201 86 2201 43 Independent claims in excess of 3	1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1201 66 2201 43 independent claims in excess or 3	1810	770	2810	385	For each additional invention to be examined (37CFR 1.129(b))	
1204 86 2204 43 ** Reissue independent claims	1801	770	2801	385	Request for Continued Examination (RCE)	
over original patent 1205 18 2205 9 "Reissue claims in excess of 20	1802	900	1802	900	Request for expedited examination of a design application	
and over original patent	Other	ee (spe	cify)			
SUBTOTAL (2) (\$) 0.00	*Redu	ced by E	Basic Fi	ling Fee	Paid SUBTOTAL (3) (\$)	0.00
**or number previously paid, if greater; For Reissues, see above						

SUBMITTED BY		(Complete (if app			(if applicable))		
Name (Print/Type)	Meliss	a J. Pytel	<u>م</u> کے	Registration No. (Attorney/Agent)	41,512	Telephone	(301) 610-5764
Signature				\L_\		Date	August 10, 2004
		\overline{U}					



In re Patent Application of: Hu et al. Docket No.: PF112P3C2US

Application No.: 10/696,002 Confirmation No.: 7776

Filed: October 30, 2003 Art Unit: 1647

For: Vascular Endothelial Growth Factor 2 Examiner: Landsman, R.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references GU and GV listed on the attached Form PTO/SB/08. Copies of the references are enclosed.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

The undersigned certifies pursuant to 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Supplemental Information Disclosure Statement. In particular, the listed references were cited in a European Supplementary Search Report (reference GV) mailed July 14, 2004, in connection with a corresponding international application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Dated: August 10, 2004

Respectfully submitted,

Melissa J. Pytel

Registration No.: 41,512

HUMAN GENOME SCIENCES, INC.

Intellectual Property Dept. 14200 Shady Grove Road Rockville, Maryland 20850 (301) 610-5764

MMW/MJP/ba



PTO/SB/08a/b (08-03)
Approved for use through 0731/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of 1

Complete if Known					
Application Number	10/696,002-Conf. #7776				
Filing Date	October 30, 2003				
First Named Inventor	Jing-Shan Hu				
Art Unit	1647				
Examiner Name	R. S. Landsman				
Attorney Docket Number	PF112P3C2US				

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	GU	VALE et al., "Percutaneous Electromechanical Mapping Demonstrates Efficacy of pVGI.1 (VEG2) in an Animal Model of Chronic Myocardial Ischemia," <i>Circulation</i> (Supplement), 100(18):I.22 (Nov. 2, 1999)			
-	GV	European Supplementary Search Report, Application No. EP 01 96 3814, mailed July 14, 2004			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	 Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.